Eagle Ridge Investment Management Buys 665 Shares of Johnson & Johnson (NYSE:JNJ)

Eagle Ridge Investment Management boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,773 shares of the company’s stock after purchasing an additional 665 shares during the period. Eagle Ridge Investment Management’s holdings in Johnson & Johnson were worth $5,607,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Vinva Investment Management Ltd boosted its holdings in shares of Johnson & Johnson by 6.8% in the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock valued at $17,988,000 after buying an additional 7,110 shares during the last quarter. Financial Counselors Inc. raised its position in Johnson & Johnson by 5.3% during the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock worth $29,996,000 after acquiring an additional 9,309 shares in the last quarter. Oregon Pacific Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $949,000. Meridian Investment Counsel Inc. increased its stake in shares of Johnson & Johnson by 19.6% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock worth $3,667,000 after purchasing an additional 3,710 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock valued at $2,858,543,000 after purchasing an additional 102,502 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.3 %

Shares of Johnson & Johnson stock opened at $153.10 on Monday. The firm’s 50-day moving average price is $147.42 and its two-hundred day moving average price is $156.08. The company has a market capitalization of $368.61 billion, a price-to-earnings ratio of 23.02, a PEG ratio of 2.46 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the firm posted $2.29 earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.24%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on JNJ. Citigroup cut their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Leerink Partners cut their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Raymond James decreased their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Finally, Bank of America decreased their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.